Anika Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials for the Incert chemically cross-linked form of hyaluronic acid are expected to begin in 1999, the company says. Incert, which is intended to act as a barrier and reduce post-operative adhesions after pelvic or abdominal surgery, also holds potential for prevention of adhesions following gynecological and general surgery, Anika maintains